EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication

Takahiko Sakaue, Hiroya Terabe, Hidetoshi Takedatsu, Takumi Kawaguchi iD

Hepatology Research · 2024-08 · 54 (8) · 729-735

DOI: 10.1111/hepr.14081 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hepatology Research, online erschienen am 17.06.2024. Verfasst von Takahiko Sakaue und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: MHLW Health Labor Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extrahepatic malignancies are the leading cause of death in patients with nonalcoholic fatty liver disease (NAFLD). Of these cancers, pancreatic cancer is one of the most lethal; however, the link between NAFLD and pancreatic cancer remains unclear. Recently, various research results have been reported on the association between NAFLD and pancreatic cancer, and the results of compiling this information revealed the following. First, the prevalence of pancreatic cancer in patients with NAFLD is at 0.26%. Second, the currently evident pathogenesis includes intrapancreatic risk factors, such as: (1) non‐alcoholic fatty pancreas disease, and (2) intraductal papillary mucinous neoplasm; and extrapancreatic risk factors, such as: (1) insulin resistance and adipocytokines, (2) proinflammatory cytokines, and (3) dysbiosis. Finally, metformin and sodium–glucose cotransporter 2 inhibitors may reduce the risk of pancreatic cancer in diabetes patients with NAFLD. In this review, we summarize the recent evidence on the epidemiology and mechanisms for NAFLD‐related pancreatic cancer. We further discuss the impact of anti‐diabetic medication on pancreatic cancer.

Schlagwörter

Stichwörter der Autor:innen

antidiabetic medicationsmetabolic dysfunction‐associated steatotic liver diseasenonalcoholic fatty liver diseasepancreatic cancer

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.

ORCID-Profile: Takumi Kawaguchi

Förderung

  • MHLW Health Labor Sciences

Zitieren

APA

Sakaue, T., Terabe, H., Takedatsu, H., & Kawaguchi, T. (2024). Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication. Hepatology Research, 54(8), 729-735. https://doi.org/10.1111/hepr.14081

Vancouver

Sakaue T, Terabe H, Takedatsu H, Kawaguchi T. Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication. Hepatology Research. 2024;54(8):729-735. doi:10.1111/hepr.14081

BibTeX
@article{Sakaue2024,
  author = {Sakaue, Takahiko and Terabe, Hiroya and Takedatsu, Hidetoshi and Kawaguchi, Takumi},
  title = {Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication},
  journal = {Hepatology Research},
  year = {2024},
  volume = {54},
  number = {8},
  pages = {729--735},
  doi = {10.1111/hepr.14081}
}
Kostenlos starten →